NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/09/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4.09 mln
Float1.02 mln
Earnings Date11/26/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
93
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-64.44
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Galmed Pharmaceuticals, founded in 2000 and based in Ramat Gan, Israel, is a medical research company working to develop new treatments for liver disease. Its lead drug candidate, Aramchol, is currently in late-stage clinical trials as a treatment for a serious liver condition linked to obesity and diabetes, with additional studies exploring its potential in HIV-related liver complications. The company is also advancing several other drug candidates targeting liver disease and related conditions. Galmed has partnerships with South Korean pharmaceutical company Samil Pharma for the sale of Aramchol in that market, as well as a collaboration with OnKai to leverage artificial intelligence in its research efforts.
